Platelet thrombin receptor antagonism and atherothrombosis

by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto

EHJVolume 31(1):17-28

January 1, 2010

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Sites of action of current and emerging antithrombotic drugs and antiplatelet agents.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Intracellular signalling pathways and phenotypic effects mediated by PAR-1 activation by thrombin in platelets.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Role of thrombin-mediated PAR-1 signalling in haemostasis vs. thrombosis: rationale for PAR-1 antagonist.38 In addition to activating PARs on platelets, thrombin facilitates fibrin formation and

protein C activation.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

PAR-1 antagonists in clinical development.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org